GlassScriptPhysician profile
Sharon Lamkin
NPI 1083678981
$2,466.84
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,924 · 2022: $392 · 2023: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $466.44 | 2021 | |
| Novo Nordisk INC | $438.19 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $401.60 | 2021-2023 | Jardiance |
| Insulet Corporation | $115.69 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $113.10 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $107.55 | 2021-2022 | |
| Dexcom, INC. | $96.02 | 2021-2022 | |
| Abbvie INC. | $87.58 | 2021-2022 | |
| Amgen INC. | $85.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $79.14 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $75.79 | 2021-2022 | |
| Amarin Pharma, INC. | $43.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.18 | 2021-2023 | |
| Mannkind Corporation | $33.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.07 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26.99 | 2021-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $23.33 | 2021 | |
| Ascensia Diabetes Care US INC. | $22.75 | 2021 | |
| Amryt Pharma Holdings LTD | $21.15 | 2021 | |
| Clarus Therapeutics INC. | $20.44 | 2021 | |
| Grt US Holding, INC. | $18.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.86 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $17.12 | 2021 | |
| Alfasigma USA, INC. | $16.39 | 2021 | |
| Tandem Diabetes Care, INC. | $15.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.59 | 2022 | |
| Cequr Corporation | $14.18 | 2021 | |
| Recordati_rare_diseases_inc. | $14.13 | 2021 | |
| Vistapharm, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lamkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.